We examine tactics used by a pharmaceutical company to maintain its monopoly on medication. They do this by forcing patients to switch from a formulation about to lose patent protection to another that has years left on patent. We expose the problem in the first piece and in the second piece we report exclusively on a lawsuit filed by the New York State Attorney General against the company that makes Namenda. In it we included audio of the CEO describing how a forced switch would allow them to hold onto their base users and keep profits from falling off a cliff. In the third piece we report on a ruling agreeing to an injunction which will keep the original Namenda on pharmacy shelves, allowing our viewers to know the outcome of an issue we first exposed.
